Xp21/A Translocation: A Rarely Considered Genetic Cause for Manifesting Carriers of Duchenne Muscular Dystrophy

Abstract

Clinically manifesting carriers of Duchenne muscular dystrophy (DMD) are rare among the pediatric population. A standardized diagnostic procedure in supposed DMD carriers entails performing a Multiplex Ligation-dependent Probe Amplification analysis of the DMD gene first, then taking a muscle biopsy to confirm reduced dystrophin levels and/or finally a complete sequencing of the DMD gene. We describe a girl with high-elevated creatine kinase, myalgia, and cardiomyopathy. Muscle biopsy showed a dystrophic pattern and nearly absent expression of dystrophin. Diagnosis could not be confirmed by molecular genetic procedures. Because of a mild mental retardation, a chromosome analysis and molecular karyotyping were performed, revealing a balanced translocation t(X;4)(p21;q31).arr(1–22,X)x2 dn with breakpoint on the X-chromosome within an intron of the DMD gene. The inactivation of the nonderivative X-chromosome was found to be in a nonrandom pattern, resulting in a functionally balanced karyotype and thus leading to a manifesting DMD carrier in this case. Chromosome analysis should be recommended in cases of genetically unsolved DMD carriers as a part of the standard genetic procedures.

Keywords

manifesting DMD carrier - balanced translocation - X-chromosome inactivation

• References

• 1 Soltanzadeh P, Friez MJ, Dunn D , et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscul Disord 2010; 20 (8) 499-504
• 2 Hoogerwaard EM, Bakker E, Ippel PF , et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 1999; 353 (9170) 2116-2119
• 3 Schade van Westrum SM, Hoogerwaard EM, Dekker L , et al. Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. Neurology 2011; 77 (1) 62-66
• 4 Mercier S, Toutain A, Toussaint A , et al. Genetic and clinical specificity of 26 symptomatic carriers for dystrophinopathies at pediatric age. Eur J Hum Genet 2013; 21 (8) 855-863
• 5 Arikawa E, Hoffman EP, Kaido M, Nonaka I, Sugita H, Arahata K. The frequency of patients with dystrophin abnormalities in a limb-girdle patient population. Neurology 1991; 41 (9) 1491-1496
• 6 Brioschi S, Gualandi F, Scotton C , et al. Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype. BMC Med Genet 2012; 13: 73
• 7 Viggiano E, Picillo E, Cirillo A, Politano L. Comparison of X-chromosome inactivation in Duchenne muscle/myocardium-manifesting carriers, non-manifesting carriers and related daughters. Clin Genet 2013; 84 (3) 265-270
• 8 Amos-Landgraf JM, Cottle A, Plenge RM , et al. X chromosome-inactivation patterns of 1,005 phenotypically unaffected females. Am J Hum Genet 2006; 79 (3) 493-499
• 9 White WM, Willard HF, Van Dyke DL, Wolff DJ. The spreading of X inactivation into autosomal material of an x;autosome translocation: evidence for a difference between autosomal and X-chromosomal DNA. Am J Hum Genet 1998; 63 (1) 20-28
• 10 Ferlini A, Neri M, Gualandi F. The medical genetics of dystrophinopathies: molecular genetic diagnosis and its impact on clinical practice. Neuromuscul Disord 2013; 23 (1) 4-14
• 11 Thorvaldsen JL, Krapp C, Willard HF, Bartolomei MS. Nonrandom X chromosome inactivation is influenced by multiple regions on the murine X chromosome. Genetics 2012; 192 (3) 1095-1107